VYNE

VYNE Therapeutics Inc. NASDAQ Listed Jan 25, 2018

Healthcare ·Biotechnology ·US · vynetherapeutics.com

$0.67

Mkt Cap $11.2M

52w Low $0.28 23.4% of range 52w High $1.96

50d MA $0.61 200d MA $0.50

P/E (TTM) -1.0x

EV/EBITDA -0.0x

P/B 1.0x

Debt/Equity 0.0x

ROE -95.4%

P/FCF -0.7x

RSI (14) —

ATR (14) —

Beta 1.95

50d MA $0.61

200d MA $0.50

Avg Volume 238.5K

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

SIC Code

2834

CIK (SEC)

1566044

Phone

800 775 7936

520 U.S. Highway 22 · Bridgewater, NJ 08807 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.20	-0.28	-40.0%	0.59	+0.4%	+0.7%	+3.0%	+0.5%	-4.5%	+6.8%	—
Nov 6, 2025	AMC	-0.19	-0.17	+10.5%	0.35	+1.9%	-0.3%	+3.0%	-1.3%	-1.6%	+4.8%	—
Aug 14, 2025	AMC	-0.23	-0.13	+43.5%	0.35	-2.8%	+0.3%	-1.9%	-3.2%	-1.8%	-1.3%	—
May 8, 2025	AMC	-0.29	-0.20	+31.0%	1.30	-2.3%	+0.0%	-3.8%	+4.8%	-3.8%	-0.8%	—
Mar 6, 2025	AMC	-0.31	-0.28	+9.7%	2.33	-2.6%	-6.0%	-9.6%	-5.1%	-1.6%	+2.7%	—
Nov 7, 2024	AMC	-0.24	-0.29	-20.8%	3.16	-0.3%	+0.0%	-4.4%	-0.7%	-3.0%	-2.4%	—
Aug 14, 2024	AMC	-0.19	-0.22	-15.8%	1.73	+0.0%	+7.5%	+0.0%	-0.5%	-1.1%	+2.2%	—
May 9, 2024	AMC	-0.24	-0.15	+37.5%	2.65	+0.8%	+0.8%	+6.0%	+2.1%	-4.5%	-2.2%	—
Feb 29, 2024	AMC	-0.50	-0.20	+60.0%	2.23	-0.4%	-0.4%	+2.7%	-1.3%	+4.4%	-1.3%	—
Nov 13, 2023	AMC	-0.76	-1.85	-143.4%	3.48	-2.0%	+2.6%	+15.4%	-3.4%	-1.8%	+1.0%	—
Aug 14, 2023	AMC	-1.99	-3.08	-54.8%	6.01	+1.7%	-19.3%	+3.1%	-5.6%	+0.6%	-5.3%	—
May 11, 2023	AMC	-2.50	-1.74	+30.4%	6.10	+10.2%	+18.5%	+6.2%	-8.2%	+1.8%	-5.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 30	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$1.44	$0.38	-73.6%	-72.4%	-8.2%	-3.5%	+3.5%	-1.4%
Apr 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.88	$1.46	-22.3%	-23.9%	+0.7%	-2.1%	-5.7%	+0.8%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.39	$2.36	-1.3%	-2.5%	-6.0%	-9.6%	-5.1%	-1.6%
Feb 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.50	$2.55	+2.0%	+0.8%	+7.1%	+1.5%	+2.2%	-5.4%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.02	$3.06	+1.3%	-8.9%	+0.4%	-6.5%	+4.7%	+2.6%
Jan 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.46	$3.50	+1.2%	+15.6%	+7.0%	-8.4%	-12.5%	-12.0%
Dec 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.50	$2.60	+4.0%	+2.8%	+15.6%	+8.8%	-1.9%	+0.6%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.16	$3.15	-0.3%	+0.0%	-4.4%	-0.7%	-3.0%	-2.4%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.85	$1.85	+0.0%	-3.2%	+2.8%	+2.2%	-2.7%	+1.6%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.73	$1.73	+0.0%	+7.5%	+0.0%	-0.5%	-1.1%	+2.2%
Jun 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.20	$2.19	-0.5%	+4.5%	+2.6%	-6.4%	-21.3%	+4.6%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.41	$2.41	+0.0%	-1.2%	+0.0%	-5.5%	+1.3%	+0.4%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.72	$2.77	+1.8%	-2.6%	+0.8%	+6.0%	+2.1%	-4.5%
May 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.62	$2.64	+0.8%	+3.4%	+6.6%	-5.9%	-2.6%	+0.8%
Feb 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.33	$2.33	+0.0%	-4.3%	-0.4%	+2.7%	-1.3%	+4.4%
Oct 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.25	$3.15	+40.3%	+23.4%	+10.1%	-2.0%	+1.7%	-0.3%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.50	$5.50	+0.0%	+9.3%	-19.3%	+3.1%	-5.6%	+0.6%
May 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.10	$6.72	+10.2%	+18.5%	+6.2%	-8.2%	+1.8%	-5.6%
May 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.10	$6.72	+10.2%	+18.5%	+6.2%	-8.2%	+1.8%	-5.6%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.29	$5.76	-21.0%	-22.9%	-2.7%	+4.0%	+1.2%	+7.5%
May 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$64.08	$65.52	+2.2%	+2.0%	-8.5%	+2.4%	+2.9%	-7.4%

Data updated apr 27, 2026 8:35am · Source: massive.com